AzTrials
AzTrials

Asphyxia NeonatorumNeoSupraNCT03133572

Neonatal Resuscitation With Supraglottic Airway Trial

A study testing Supraglottic airway and Face-mask in people with Asphyxia Neonatorum, run by Centre For International Health at 1 site in Uganda.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

Mortality rates from birth asphyxia in low-income countries remain very high. Face mask ventilation (FMV) is the most common method of resuscitating neonates in such settings. It is mostly performed by midwives but may not always be satisfactory. Read more about this study

Who is it for?
Ages Up to 10 minutes
Conditions the study is for
Asphyxia Neonatorum
What is being tested?
Supraglottic airway and Face-mask
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,163 participants
Where
1 siteUganda
Study dates
8 May 2018to Dec 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Up to 10 minutes
  • All sexes
  • No healthy volunteers
  • Child

Who may be able to join

  • Inborn baby (=born in the hospital)
  • Expected ≥ 34-week gestation
  • Expected birth weight ≥ 2000 g
  • Need for PPV at birth
  • Parental consent

Who cannot join

  • Major malformations (incompatible with sustained life or affecting the airways)

Trial locations and contacts

1 site in 1 country.

Uganda1 site
  • Mulago National Referral Hospital

    Kampala

Other trials in Uganda

About this study

Official title: Neonatal Supraglottic Airway Trial: A Single-centre, Open-label, Randomized Clinical Trial to Evaluate the Efficacy of I-gel® Supraglottic Airway Used in Neonatal Resuscitation in Reducing Early Neonatal Mortality and Morbidity

Mortality rates from birth asphyxia in low-income countries remain very high. Face mask ventilation (FMV) is the most common method of resuscitating neonates in such settings. It is mostly performed by midwives but may not always be satisfactory. The i-gel® is a cuffless supraglottic airway which is easy to insert and provides an efficient seal that prevents air leakage with the potential to enhance the performance of neonatal resuscitation. Midwives can be trained in a short time to use this method. A pilot study in Uganda has demonstrated that midwives can safely perform resuscitation of newborn with the i-gel.

OBJECTIVE To investigate whether the use of a cuffless supraglottic airway compared to face-mask ventilation during neonatal resuscitation can reduce early neonatal death (before 7 days of life) or morbidity in neonatal encephalopathy (NE) in asphyxiated neonates.

Read more

STUDY DESIGN, SETTING AND POPULATION A single-centre randomized clinical trial will be conducted at Mulago National Referral Hospital, Kampala, Uganda, among asphyxiated neonates in the delivery units. Prior to the intervention, all staff in the labour ward performing resuscitation will receive training according to the HBB curriculum with a special module for training on supraglottic airway insertion. Resuscitation will be performed according to international guidelines.

UTILITY OF THE STUDY It is crucial to explore alternative, cost-effective modalities that not only would reduce mortality, but also the burden of neurological damage in survivors.

Read the detailed description

One of the targets in the SDG-3 is to reduce neonatal mortality to less than 12 per 1000 live births by 2030. This will require considerable effort in many low-income countries. Perinatal mortality contributes to 40% of infant mortality in Uganda. Early neonatal death from birth asphyxia (BA) could be as high 60%. New evidence-based strategies are needed to reduce mortality from BA in order to achieve SDG-3 by 2030.

Optimal care of the depressed newborn is crucial to prevent and manage BA. The challenge in low-income settings is that highly qualified staff is not readily available to attend to the newborn who require their expertise. In most cases, the midwives are the most skilled personal attending to deliveries and also responsible for resuscitating newborns. At present in low-income settings, FMV is the commonly used method for resuscitating depressed newborn. Easy-to-use equipment such as a supraglottic airway could contribute to obtain more effective ventilation, and improve the outcome of the infant.

This trial is based on a previous pilot trial ClinicalTrials.gov Identifier: NCT02042118.

Primary objective

  • To assess if the proportion of either early neonatal death or neonatal encephalopathy (admission to NICU with a Thompson score of 11 or above in day 1-5 during hospitalisation), can be decreased from 40 % in the control arm (using FM) to 30 % or less in the intervention arm (using i-gel supraglottic airway), a 25% decrease.

Secondary objectives

  • To assess the safety of a supraglottic airway in the hands of lower cadre (non-doctor) birth attendants in Africa.
  • To assess if the proportion of very early and early neonatal deaths is lower in the intervention arm compared to the control arm.
  • To assess if the proportion of neonatal encephalopathy (admission to NICU with maximum Thompson score 11 or above), is lower in the intervention arm compared to the control arm.
  • To assess if the proportion of neonatal encephalopathy (admission to Neonatal Intensive Care Unit - NICU - with maximum Thompson score 7 or above), is lower in the intervention arm compared to the control arm.
  • To assess if hospital admission rate in the first 7 days of life is lower in the intervention arm compared to the control arm.
  • To assess the need of advanced resuscitation in the intervention arm compared to the control arm.

Study justification and significance

Training midwives and other birth-attendants can save lives. However, delivering effective positive pressure ventilation (PPV) with FM is a delicate task that requires continuous (re)training. In a previous phase II trial (NCT02042118), it has been shown that a supraglottic airway is safe to use, even in the hands of midwives and with the potential to deliver efficient PPV and perhaps even improve outcome of asphyxiated babies. The cuffless i-gel is simple to use and could therefore be the ideal device to resuscitate newborn when experienced physicians are not available.

Prior to interventions: training midwives in neonatal resuscitation skills

Helping Babies Breathe (HBB) is an evidence-based educational program to teach neonatal resuscitation techniques in resource-limited areas. It is an initiative of the American Academy of Pediatrics (AAP) in collaboration with the World Health Organization (WHO), US Agency for International Development (USAID), Saving Newborn Lives, the National Institute of Child Health and Development, and a number of other global health organizations.

The objective of HBB is to train birth attendants in developing countries in the essential skills of newborn resuscitation, with the goal of having at least one person who is skilled in neonatal resuscitation at the birth of every baby.

The second edition of HBB is now available and will be used in the training.

Study procedures

It is estimated that around 5-10 % of babies born will need ventilation as part of the resuscitation. This randomized trial will include all babies eligible for resuscitation. All newborns in need of resuscitation will be randomized to receive initial treatment using either:

  • Supraglottic airway (intervention arm) or
  • Face mask (active comparator arm).

The midwife will immediately move the babies not responding to stimulation to the resuscitation area. Ventilation with supraglottic airway or face mask will be initiated immediately. Apgar score and admission to the neonatal ward will be recorded by a research assistant. The intervention may be recorded on video to ensure quality assurance and data collection.

If the infant is hospitalised, daily assessment of Thompson score will be made by a skilled paediatrician/physician. A follow-up visit on day 7 (or later) will determine the outcome (if the infant is alive or not) together with the assessments of Thompson score.

Being tested
Supraglottic airway, Face-mask
Medical subject headings
Asphyxia Neonatorum

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Supraglottic airwayDevice

    Also called i-gel, supraglottic airway device

    Instead of using a conventional face mask to provide positive pressure ventilation during neonatal resuscitation we are using a supraglottic airway and a conventional bag.

  • Face-maskDevice

    In order to provide positive pressure ventilation during neonatal resuscitation we are using a conventional face-mask and a conventional bag.

Study groups in NCT03133572
Study groupRoleWhat they receive
Supraglottic airwayExperimentalAll newborns in need of resuscitation in this arm will receive initial treatment with positive pressure ventilation using a supraglottic airway and a bag.
Receives: Device: Supraglottic airway
Face-maskActive comparatorAll newborns in need of resuscitation in this arm will receive initial treatment with positive pressure ventilation using a face-mask and a bag.
Receives: Device: Face-mask

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Composite outcome of either a) early neonatal death or b) neonatal encephalopathy

    A composite outcome of a) early neonatal death (within 7 days) b) neonatal encephalopathy (admission to NICU with a Thompson score of 11 or above in day 1-5 during hospitalisation).

    Measured: Day 7 of life

Secondary outcomes (7)
  1. Number of adverse events (AEs) and serious adverse events (SAEs)

    Safety of i-gel in the hands of non-doctor birth attendants (AEs and SAEs)

    Measured: Day 7 of life

  2. Early neonatal death

    Early neonatal death (within 7 days)

    Measured: Day 7 of life

  3. Very early neonatal death

    Very early neonatal death (within 24 hours)

    Measured: Day 1 of life

  4. Neonatal encephalopathy

    Neonatal encephalopathy (admission to NICU with a Thompson score of 11 or above in day 1-5 during hospitalisation).

    Measured: Day 7 of life

  5. Mild neonatal encephalopathy

    Neonatal encephalopathy (admission to NICU with a Thompson score of 7 or above in day 1-5 during hospitalisation).

    Measured: Day 7 of life

  6. Any hospital admission

    Any hospital admission

    Measured: Day 7 of life

  7. Advanced resuscitation

    Advanced resuscitation including intervention by supervising physician

    Measured: Day 7 of life

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted28 Apr 2017
  2. Study start8 May 2018
  3. Primary completion12 Aug 2019
  4. Study completionDec 2021 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Day by day, infants will be randomized to either of the arms.
Masking
Single blind
Who is masked
Outcomes assessor
Enrolment
1,163 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT03133572
Sponsor's protocol ID
NeoSupra
Acronym
NeoSupra
Status last verified
Jun 2020
First submitted
26 Apr 2017
Last updated
29 Jun 2020
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Publications

  • Pejovic NJ, Trevisanuto D, Nankunda J, Tylleskar T. Pilot manikin study showed that a supraglottic airway device improved simulated neonatal ventilation in a low-resource setting. Acta Paediatr. 2016 Dec;105(12):1440-1443. doi: 10.1111/apa.13565.

    PubMed 27582031
  • Pejovic NJ, Trevisanuto D, Lubulwa C, Myrnerts Hook S, Cavallin F, Byamugisha J, Nankunda J, Tylleskar T. Neonatal resuscitation using a laryngeal mask airway: a randomised trial in Uganda. Arch Dis Child. 2018 Mar;103(3):255-260. doi: 10.1136/archdischild-2017-312934. Epub 2017 Sep 14.

    PubMed 28912163
  • Pejovic NJ, Myrnerts Hook S, Byamugisha J, Alfven T, Lubulwa C, Cavallin F, Nankunda J, Ersdal H, Segafredo G, Blennow M, Trevisanuto D, Tylleskar T. Neonatal resuscitation using a supraglottic airway device for improved mortality and morbidity outcomes in a low-income country: study protocol for a randomized trial. Trials. 2019 Jul 19;20(1):444. doi: 10.1186/s13063-019-3455-8.

    PubMed 31324213
  • Larsson M, Myrnerts Hook S, Mpamize A, Tylleskar T, Lubulwa C, Trevisanuto D, Elfving K, Pejovic NJ. Oxygen saturation after birth in resuscitated neonates in Uganda: a video-based observational study. BMJ Paediatr Open. 2022 Jan;6(1):e001225. doi: 10.1136/bmjpo-2021-001225.

    PubMed 35258476
  • Pejovic NJ, Myrnerts Hook S, Byamugisha J, Alfven T, Lubulwa C, Cavallin F, Nankunda J, Ersdal H, Blennow M, Trevisanuto D, Tylleskar T. A Randomized Trial of Laryngeal Mask Airway in Neonatal Resuscitation. N Engl J Med. 2020 Nov 26;383(22):2138-2147. doi: 10.1056/NEJMoa2005333.

    PubMed 33252870

Questions about this trial

What is this clinical trial studying?

A study testing Supraglottic airway and Face-mask in people with Asphyxia Neonatorum, run by Centre For International Health at 1 site in Uganda.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 29 Jun 2020. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Uganda. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Composite outcome of either a) early neonatal death or b) neonatal encephalopathy (time frame: Day 7 of life). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT03133572, which also lists 5 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jun 2020.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in